Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 9:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: $5 off Clear all
Completed Not applicable Interventional Accepts healthy volunteers

An Active Approach to Treat Amblyopia: Video Game Play

NCT01223716
View directory record Official record
Conditions
Amblyopia
Interventions
Perceptual learning, Video Game, Crossover (Occlusion therapy + Video Game)
Behavioral
Lead sponsor
University of California, Berkeley
Other
Eligibility
5 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated May 16, 2016 · Synced Sep 24, 2026, 9:03 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Study of SST-0225 Topical Ibuprofen Cream in the Treatment of Delayed Onset Muscle Soreness (DOMS)

NCT02597634
View directory record Official record
Conditions
Delayed Onset Muscle Soreness, DOMS
Interventions
SST-0225, Placebo
Drug
Lead sponsor
Strategic Science & Technologies, LLC
Industry
Eligibility
16 Years to 65 Years
Enrollment
156 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
3
States / cities
Hollywood, Florida • South Miami, Florida • Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 12, 2016 · Synced Sep 24, 2026, 9:03 PM EDT
Completed Phase 1 Interventional

Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal Adenocarcinoma

NCT05440942
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma
Interventions
Trametinib, Ruxolitinib, Retifanlimab
Drug
Lead sponsor
Peter Hosein, MD
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Sep 24, 2026, 9:03 PM EDT
Recruiting Phase 1 Interventional

DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma

NCT04248569
View directory record Official record
Conditions
Fibrolamellar Hepatocellular Carcinoma (FLC)
Interventions
DNAJB1-PRKACA peptide vaccine, Nivolumab, Ipilimumab
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
12 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2034
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Sep 24, 2026, 9:03 PM EDT
Completed Phase 2 Interventional Results available

Study to Assess Enobosarm (GTx-024) in Postmenopausal Women With Stress Urinary Incontinence

NCT03241342
View directory record Official record
Conditions
Stress Urinary Incontinence
Interventions
GTx 024, Placebo
Drug
Lead sponsor
GTx
Industry
Eligibility
18 Years to 80 Years · Female only
Enrollment
491 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
62
States / cities
Homewood, Alabama • Mobile, Alabama • Anchorage, Alaska + 57 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2021 · Synced Sep 24, 2026, 9:03 PM EDT
Active, not recruiting Phase 1 Interventional

SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS

NCT06325748
View directory record Official record
Conditions
AML/MDS, CD33 Expressing Hematological Malignancies, FLT3 Expressing Hematological Malignancies
Interventions
SENTI-202
Biological
Lead sponsor
Senti Biosciences
Industry
Eligibility
18 Years to 74 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2040
U.S. locations
6
States / cities
Los Angeles, California • Denver, Colorado • Jacksonville, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Sep 24, 2026, 9:03 PM EDT
Completed Phase 2 Interventional

Sensory-Targeted Ankle Rehabilitation Strategies (STARS)

NCT01541657
View directory record Official record
Conditions
Chronic Ankle Instability
Interventions
Ankle Joint Mobilization, Foot Massage, Calf Stretching
Other
Lead sponsor
Joel Thompson
Other
Eligibility
18 Years to 45 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
2
States / cities
Ithaca, New York • Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 25, 2018 · Synced Sep 24, 2026, 9:03 PM EDT
Recruiting Phase 1 Interventional

Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy

NCT06065371
View directory record Official record
Conditions
Gastrointestinal Cancer
Interventions
Capecitabine, Sacituzumab govetican
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Sep 24, 2026, 9:03 PM EDT
Active, not recruiting Phase 2 Interventional

Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)

NCT03944772
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Osimertinib, Savolitinib, Gefitinib, Necitumumab, Durvalumab, Carboplatin, Pemetrexed, Alectinib, Selpercatinib, Selumetinib, Etoposide, Cisplatin, Datopotamab deruxtecan
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
16
States / cities
Duarte, California • Los Angeles, California • Sacramento, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2025 · Synced Sep 24, 2026, 9:03 PM EDT
Completed Phase 2 Interventional

Single Center Study of Apremilast for the Treatment of Hidradenitis Suppurativa

NCT02695212
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Apremilast
Drug
Lead sponsor
Florida Academic Dermatology Centers
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated Apr 1, 2019 · Synced Sep 24, 2026, 9:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Single and Repeated Doses of Topical GSK1278863

NCT01831804
View directory record Official record
Conditions
Wound Healing
Interventions
GSK1278863, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 90 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
7
States / cities
Castro Valley, California • Washington D.C., District of Columbia • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2019 · Synced Sep 24, 2026, 9:03 PM EDT
Recruiting Phase 1 Interventional

TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT

NCT07302776
View directory record Official record
Conditions
GVHD, Hematopoietic Cell Transplantation (HCT), Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes, Myelofibrosis (MF), Chronic Myeloid Leukemia (CML), Chronic Myelomonocytic Leukemia (CMML)
Interventions
Tacrolimus, Early Tacrolimus Taper Strategy
Drug · Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 24, 2026, 9:03 PM EDT
Completed Phase 1 Interventional

A Phase 1b/2a, Open-Label, Multi-Center Study of Tivozanib (AV-951) in Combination With Paclitaxel in Subjects With Advanced or Metastatic Breast Cancer

NCT00717340
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
tivozanib (AV-951) + paclitaxel
Drug
Lead sponsor
AVEO Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 27, 2012 · Synced Sep 24, 2026, 9:03 PM EDT
Completed Phase 1 Interventional

A Trial of mFOLFIRI With MEK162 in Patients With Advanced RAS (HRAS, NRAS, or KRAS) Positive Metastatic Colorectal Cancers

NCT02613650
View directory record Official record
Conditions
Advanced KRAS Positive Metastatic Colorectal Cancer
Interventions
MEK162 and mFOLFIRI
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Sep 24, 2026, 9:03 PM EDT
Terminated Phase 2 Interventional Results available

Lactated Ringer's Versus 5% Human Albumin: Cardiac Surgical Patients

NCT02654782
View directory record Official record
Conditions
Hemodynamic Stability
Interventions
Lactated Ringer's, 5% Human Albumin
Drug
Lead sponsor
William C. Oliver
Other
Eligibility
18 Years to 99 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 15, 2019 · Synced Sep 24, 2026, 9:03 PM EDT
Completed Phase 1 Interventional Results available

Continuous Dosing of BAY73-4506 in Patients With Advanced Malignancies

NCT01117623
View directory record Official record
Conditions
Neoplasm
Interventions
Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 20 mg, Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 40 mg, Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 100 mg, Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 120 mg, Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 140 mg, HCC Child-Pugh A expansion cohort: Regorafenib 100 mg, HCC Child-Pugh B expansion cohort: Regorafenib 100 mg, NSCLC expansion cohort: Regorafenib 100 mg
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
5
States / cities
Los Angeles, California • Aurora, Colorado • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2015 · Synced Sep 24, 2026, 9:03 PM EDT
Recruiting Not applicable Interventional

Improving Alcohol and Substance Use Care Access, Outcome, Equity During the Reproductive Years

NCT05910580
View directory record Official record
Conditions
Alcohol-Related Disorders, Substance-Related Disorders, Mental Health, Reproductive Health, Sexual Health, Sexually Transmitted Diseases, Contraception, Maternal Health, Pregnancy, Women's Health
Interventions
Screening, Brief Intervention, and Referral to Treatment (SBIRT)
Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
4
States / cities
Boston, Massachusetts • Marlborough, Massachusetts • Springfield, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Sep 24, 2026, 9:03 PM EDT
Completed Phase 2 Interventional Results available

A Dose-Finding Study of GSK2894512 Cream in Subjects With Plaque Psoriasis

NCT02564042
View directory record Official record
Conditions
Psoriasis
Interventions
GSK2894512 1% Cream, GSK2894512 0.5% Cream, Vehicle cream
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
18
States / cities
San Diego, California • North Logan, Connecticut • Miami, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2017 · Synced Sep 24, 2026, 9:03 PM EDT
Completed No phase listed Interventional Accepts healthy volunteers Results available

Task Augmentation of Transcranial Magnetic Stimulation (TMS)

NCT04586205
View directory record Official record
Conditions
Healthy
Interventions
active TMS, sham TMS, IASP Task, SST Task, MRI
Device · Behavioral · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 60 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 30, 2025 · Synced Sep 24, 2026, 9:03 PM EDT
Completed Not applicable Interventional Results available

Depression Intervention Among Gay and Bisexual Men Receiving Treatment for Methamphetamine Use

NCT03864653
View directory record Official record
Conditions
HIV/AIDS, Methamphetamine Abuse, Depression
Interventions
MoodGym
Behavioral
Lead sponsor
Friends Research Institute, Inc.
Other
Eligibility
Male only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 8, 2020 · Synced Sep 24, 2026, 9:03 PM EDT
Active, not recruiting Phase 2 Interventional

A Modified Dose of Rabbit Anti-thymocyte Globulin (rATG) in Children and Adults Receiving Treatment to Help Prepare Their Bodies for a Bone Marrow Transplant

NCT04872595
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML), Acute Lymphoid Leukemia (ALL), Myelodysplastic Syndromes (MDS)
Interventions
Personalized rATG (P-rATG), Hyper fractionated total body irradiation, Thiotepa, Cyclophosphamide, GCSF, Busulfan, Melphalan, Fludarabine
Other · Radiation · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
4 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 24, 2026, 9:03 PM EDT
Completed Not applicable Interventional Results available

Transcranial Direct Current Stimulation for Improving Gait Training in Stroke

NCT01807637
View directory record Official record
Conditions
Stroke, Cerebral Vascular Accident
Interventions
transcranial direct current stim (tDCS)
Device
Lead sponsor
University of Arkansas
Other
Eligibility
21 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
2
States / cities
Conway, Arkansas • Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Dec 10, 2018 · Synced Sep 24, 2026, 9:03 PM EDT
Completed Early Phase 1 Interventional

Pharmacologic and Clinical Testing of a D1 Agonist for Cognitive Enhancement in Neuropsychiatric Disorders

NCT01519557
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
DAR-100A, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 55 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 3, 2015 · Synced Sep 24, 2026, 9:03 PM EDT
Completed Phase 2 Interventional Results available

Open-Label Extension Study to Assess the Safety and Seizure Frequency Associated With Lacosamide for Primary Generalized Tonic-Clonic Seizures in Subjects With Epilepsy

NCT01118962
View directory record Official record
Conditions
Epilepsy
Interventions
Lacosamide
Drug
Lead sponsor
UCB BIOSCIENCES, Inc.
Industry
Eligibility
16 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
19
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Aurora, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2018 · Synced Sep 24, 2026, 9:03 PM EDT